IOBTライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:39):

Stats
本日の出来高	23 188.00
平均出来高	138 441
時価総額	97.50M
EPS	$0 ( 2024-03-12 )
次の収益日	( $-0.370 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.750
ATR14	$0.0200 (1.35%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Zocca Mai-britt	Buy	750 000	Stock Option (Right to Buy)
2024-03-15	Sullivan Amy	Buy	280 000	Stock Option (Right to Buy)
2024-03-15	Smith Devin Whittemore	Buy	185 000	Stock Option (Right to Buy)
2024-03-15	Burkavage Brian	Buy	50 000	Stock Option (Right to Buy)
2024-03-15	Ahmad Qasim Iftikhar	Buy	280 000	Stock Option (Right to Buy)

INSIDER POWER
96.12
Last 87 transactions
Buy: 67 695 200 \| Sell: 7 604 578

ボリューム相関

長: -0.14 (neutral)

短: 1.00 (very strong)

Signal:(49.53) Expect same movement, but be aware

IO Biotech, Inc. 相関

10 最も正の相関
PTRA	0.957
FRST	0.952
SGMO	0.951
MOFG	0.95
SMBC	0.944
SPFI	0.943
CBAN	0.942
ABCB	0.941
ALTO	0.941
FMBH	0.94

10 最も負の相関
DRNA	-0.906
SGEN	-0.889
RPHM	-0.884
BLPH	-0.881
TZPS	-0.88
EBACU	-0.88
KBAL	-0.879
ALDX	-0.879
MLAI	-0.879
QADB	-0.876

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

IO Biotech, Inc. 相関 - 通貨/商品

-0.27
( neutral )

0.31
( neutral )

0.00
( neutral )

-0.16
( neutral )

0.29
( neutral )

0.28
( neutral )

IO Biotech, Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-756 000 (0.00 %)
EPS:	$-1.980

FY	2023
収益:	$0
総利益:	$-756 000 (0.00 %)
EPS:	$-1.980

FY	2022
収益:	$0
総利益:	$-540 000 (0.00 %)
EPS:	$-2.48

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-15.51

Financial Reports:

No articles found.

IO Biotech, Inc.

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.